Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
41
HYPD Quote, Financials, Valuation and Earnings
Last price:
$4.11
Seasonality move
:
-7.39%
Day range:
$3.50 - $4.54
52-week range:
$0.85 - $17.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
107.31x
P/B ratio:
0.47x
Volume:
956.3K
Avg. volume:
394.5K
1-year change:
102.94%
Market cap:
$33.5M
Revenue:
$57.3K
EPS (TTM):
-$21.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
$500K | -- | 1679.36% | -- | $5.88 |
|
DARE
Daré Bioscience, Inc.
|
$765K | -$0.43 | 2911.81% | -13.48% | $10.75 |
|
DVAX
Dynavax Technologies Corp.
|
$80.3M | $0.08 | 11.43% | 73.54% | $20.50 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $204.63 |
|
OMER
Omeros Corp.
|
-- | $0.16 | -- | -2.38% | $38.00 |
|
VTGN
Vistagen Therapeutics, Inc.
|
$139.5K | -$0.49 | -40.39% | -5.71% | $0.97 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
$4.14 | $5.88 | $33.5M | -- | $0.00 | 0% | 107.31x |
|
DARE
Daré Bioscience, Inc.
|
$1.69 | $10.75 | $24.1M | 95.38x | $0.00 | 0% | 341.15x |
|
DVAX
Dynavax Technologies Corp.
|
$15.50 | $20.50 | $1.8B | 54.00x | $0.00 | 0% | 6.48x |
|
GOVX
GeoVax Labs, Inc.
|
$2.67 | $204.63 | $4.6M | -- | $0.00 | 0% | 2.75x |
|
OMER
Omeros Corp.
|
$11.23 | $38.00 | $796.2M | -- | $0.00 | 0% | -- |
|
VTGN
Vistagen Therapeutics, Inc.
|
$0.56 | $0.97 | $22.2M | -- | $0.00 | 0% | 19.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
10.72% | 24.580 | 13.53% | 2.04x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | -0.176 | 27.91% | 1.09x |
|
DVAX
Dynavax Technologies Corp.
|
35.13% | -0.783 | 24.82% | 6.74x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 2.066 | -- | 2.75x |
|
OMER
Omeros Corp.
|
254.22% | -2.595 | 126.5% | 0.76x |
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 1.895 | 1.35% | 5.66x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HYPD
Hyperion DeFi, Inc.
|
$302.5K | -$2.7M | -90.16% | -143.24% | -881.16% | -$2.8M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
DVAX
Dynavax Technologies Corp.
|
$80.5M | $21.3M | -5.15% | -7.65% | 22.42% | $32.6M |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
Hyperion DeFi, Inc. vs. Competitors
-
Which has Higher Returns HYPD or DARE?
Daré Bioscience, Inc. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of -154904.35%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About HYPD or DARE?
Hyperion DeFi, Inc. has a consensus price target of $5.88, signalling upside risk potential of 41.91%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 536.1%. Given that Daré Bioscience, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.2 0 0 DAREDaré Bioscience, Inc.3 0 0 -
Is HYPD or DARE More Risky?
Hyperion DeFi, Inc. has a beta of 2.691, which suggesting that the stock is 169.084% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.886%.
-
Which is a Better Dividend Stock HYPD or DARE?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or DARE?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Hyperion DeFi, Inc.'s net income of $6.6M is higher than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 107.31x versus 341.15x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.107.31x -- $302.5K $6.6M DAREDaré Bioscience, Inc.341.15x 95.38x $2.3K -$3.6M
-
Which has Higher Returns HYPD or DVAX?
Dynavax Technologies Corp. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of 28.38%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Dynavax Technologies Corp.'s return on equity of -7.65%.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M -
What do Analysts Say About HYPD or DVAX?
Hyperion DeFi, Inc. has a consensus price target of $5.88, signalling upside risk potential of 41.91%. On the other hand Dynavax Technologies Corp. has an analysts' consensus of $20.50 which suggests that it could grow by 41.94%. Given that Dynavax Technologies Corp. has higher upside potential than Hyperion DeFi, Inc., analysts believe Dynavax Technologies Corp. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.2 0 0 DVAXDynavax Technologies Corp.1 1 1 -
Is HYPD or DVAX More Risky?
Hyperion DeFi, Inc. has a beta of 2.691, which suggesting that the stock is 169.084% more volatile than S&P 500. In comparison Dynavax Technologies Corp. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.716%.
-
Which is a Better Dividend Stock HYPD or DVAX?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Dynavax Technologies Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or DVAX?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are smaller than Dynavax Technologies Corp. quarterly revenues of $94.9M. Hyperion DeFi, Inc.'s net income of $6.6M is lower than Dynavax Technologies Corp.'s net income of $26.9M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Dynavax Technologies Corp.'s PE ratio is 54.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 107.31x versus 6.48x for Dynavax Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.107.31x -- $302.5K $6.6M DVAXDynavax Technologies Corp.6.48x 54.00x $94.9M $26.9M
-
Which has Higher Returns HYPD or GOVX?
GeoVax Labs, Inc. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of -630.04%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About HYPD or GOVX?
Hyperion DeFi, Inc. has a consensus price target of $5.88, signalling upside risk potential of 41.91%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $204.63 which suggests that it could grow by 7563.86%. Given that GeoVax Labs, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.2 0 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is HYPD or GOVX More Risky?
Hyperion DeFi, Inc. has a beta of 2.691, which suggesting that the stock is 169.084% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.768, suggesting its more volatile than the S&P 500 by 276.828%.
-
Which is a Better Dividend Stock HYPD or GOVX?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or GOVX?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Hyperion DeFi, Inc.'s net income of $6.6M is higher than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 107.31x versus 2.75x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.107.31x -- $302.5K $6.6M GOVXGeoVax Labs, Inc.2.75x -- -- -$6.3M
-
Which has Higher Returns HYPD or OMER?
Omeros Corp. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of --. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About HYPD or OMER?
Hyperion DeFi, Inc. has a consensus price target of $5.88, signalling upside risk potential of 41.91%. On the other hand Omeros Corp. has an analysts' consensus of $38.00 which suggests that it could grow by 238.38%. Given that Omeros Corp. has higher upside potential than Hyperion DeFi, Inc., analysts believe Omeros Corp. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.2 0 0 OMEROmeros Corp.2 2 0 -
Is HYPD or OMER More Risky?
Hyperion DeFi, Inc. has a beta of 2.691, which suggesting that the stock is 169.084% more volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.446, suggesting its more volatile than the S&P 500 by 144.588%.
-
Which is a Better Dividend Stock HYPD or OMER?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or OMER?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than Omeros Corp. quarterly revenues of --. Hyperion DeFi, Inc.'s net income of $6.6M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 107.31x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.107.31x -- $302.5K $6.6M OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns HYPD or VTGN?
Vistagen Therapeutics, Inc. has a net margin of -- compared to Hyperion DeFi, Inc.'s net margin of -7525.97%. Hyperion DeFi, Inc.'s return on equity of -143.24% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.
Company Gross Margin Earnings Per Share Invested Capital HYPDHyperion DeFi, Inc.-- $0.05 $79.2M VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M -
What do Analysts Say About HYPD or VTGN?
Hyperion DeFi, Inc. has a consensus price target of $5.88, signalling upside risk potential of 41.91%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 71.64%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe Vistagen Therapeutics, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HYPDHyperion DeFi, Inc.2 0 0 VTGNVistagen Therapeutics, Inc.0 5 0 -
Is HYPD or VTGN More Risky?
Hyperion DeFi, Inc. has a beta of 2.691, which suggesting that the stock is 169.084% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.324, suggesting its less volatile than the S&P 500 by 67.572%.
-
Which is a Better Dividend Stock HYPD or VTGN?
Hyperion DeFi, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hyperion DeFi, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HYPD or VTGN?
Hyperion DeFi, Inc. quarterly revenues are $302.5K, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Hyperion DeFi, Inc.'s net income of $6.6M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Hyperion DeFi, Inc.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hyperion DeFi, Inc. is 107.31x versus 19.77x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HYPDHyperion DeFi, Inc.107.31x -- $302.5K $6.6M VTGNVistagen Therapeutics, Inc.19.77x -- $258K -$19.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
